LXRX: Lexicon Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals (LXRX) focuses on developing medications to correct metabolic disorders. The company's price evolution reflects the dynamics of the 0.00 indicator. Business growth relies on the launch of Inpefa to combat cardiac pathologies, the study of renal diseases, and the search for neuropathy treatments. Entering the sales stage has allowed the company to diversify its asset portfolio, reducing reliance on trials and creating a stable profit stream in the US.

LXRX (Lexicon Pharmaceuticals Inc) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

LXRX (Lexicon Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Lexicon Pharmaceuticals, Inc.|LXRX - Fair Value Consensus
- market capitalization information:
Market Value Lexicon Pharmaceuticals, Inc.|LXRX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Lexicon Pharmaceuticals|LXRX - Book Capitalization|Market Cap to Net Assets Ratio lexpharma.com|LXRX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Lexicon Pharmaceuticals|LXRX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Lexicon Pharmaceuticals|LXRX - Company Cumulative Debt|Debt to Book Value Lexicon Pharmaceuticals, Inc.|LXRX - Amount of Long-Term Liabilities|Company Short-Term Debts Lexicon Pharmaceuticals|Quick Ratio lexpharma.com
- net income and valuation multiples indicators:
LXRX - Company Net Income
Basic company analysis:Lexicon Pharmaceuticals, Inc. - LXRX
Mass-produced product of Lexicon Corp

When analyzing an issuer's creditworthiness, assessing the risk of a liquidity shortfall is critically important. This indicator aggregates all current liabilities due for repayment within the coming year. For Lexicon Pharmaceuticals (LXRX), such obligations are directly linked to the funding of drug development for diabetes and heart failure. The trend in short-term liabilities reflects a balance between R&D investments and solvency. An upward curve signals increasing financial pressure on operating activities.

Who Lexicon Pharmaceuticals competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|Matinas BioPharma Holdings, Inc. - Company Short-Term Debt|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Galecto Inc|CTCX (Carmell Corp) - Company Current Liabilities|Company Short-Term Indebtedness LUMO|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|radiuspharm.com (RDUS) - Short-Term Debt Volume